FundLens
23
Pharma & HealthcareAvoid

Quant Healthcare

Quant · Direct–Growth · rank #19 of 19 by Smart Score

Data updated

Trailing returns

vs Nifty 500 (index-fund proxy)
1 Year
19.9%
+19.2% vs index
3 Years
20.1%
+8.6% vs index
5 Years
—
Since launch
21.7%

Year-by-year performance

last entry = YTD
2024
+31.9%
2025
-3.6%
2026
+23.9%

Why this score

Quant Healthcare scores 23/100 — #19 of 19 Pharma & Healthcare fund (Avoid). The main drag is its volatility (better than only 3% of peers).

Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.

Volatility18.22 · 3rd percentile in category
Expense ratio1.62% · 3rd percentile in category
Sharpe ratio0.85 · 25th percentile in category
Alpha2.25 · 16th percentile in category
3Y return20.14% · 38th percentile in category
Sortino ratio1.08 · 23rd percentile in category

Top holdings

top 5 = 48.3% of portfolio
1.Zydus Lifesciences Ltd10.25%
2.Divi's Laboratories Ltd.9.92%
3.Aurobindo Pharma Ltd9.83%
4.Glenmark Pharmaceuticals Limited9.38%
5.Glaxosmithkline Pharmaceuticals Ltd8.89%

16 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.

Other Pharma & Healthcare funds